Medpace (NASDAQ:MEDP) Releases FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 16.680-17.500 for the period, compared to the consensus estimate of 17.230. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MEDP. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their price objective for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Leerink Partners cut their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Barclays upgraded shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective on the stock in a report on Friday, March 6th. Royal Bank Of Canada initiated coverage on shares of Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price on the stock. Finally, Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price on the stock in a report on Tuesday, February 10th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $486.67.

Medpace Price Performance

MEDP traded down $6.44 during mid-day trading on Wednesday, hitting $508.46. The stock had a trading volume of 425,677 shares, compared to its average volume of 343,719. The stock’s fifty day simple moving average is $469.72 and its 200-day simple moving average is $537.76. The firm has a market capitalization of $14.52 billion, a price-to-earnings ratio of 33.23, a price-to-earnings-growth ratio of 2.49 and a beta of 1.39. Medpace has a 1-year low of $282.84 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts expect that Medpace will post 17.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 20.50% of the stock is currently owned by corporate insiders.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Zacks highlights Medpace’s growth attributes — strong revenue and earnings growth, high ROE, and long-term pipeline potential — arguing MEDP remains a solid growth stock that could deliver exceptional returns if execution continues. Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think “Yes”
• Neutral Sentiment: Cincinnati plans a bike path near Medpace’s Madisonville headquarters — a local infrastructure project with limited direct financial impact but positive for community relations and employee access. Cincinnati to build bike path near headquarters of one of region’s largest companies
• Neutral Sentiment: Market previews and analyst notes ahead of Medpace’s Q1 report could drive volatility around the print; investors should watch guidance commentary vs. expectations. Medpace (MEDP) Q1 Earnings: What To Expect
• Negative Sentiment: Multiple law firms have filed claims or are soliciting lead plaintiffs in a securities class action alleging Medpace overstated growth projections and harmed investors (class period: April 22, 2025 — February 9, 2026). Firms are urging investors to seek lead?plaintiff status before a June 8, 2026 deadline — the surge of notices increases legal overhang and headline risk that likely pressured the stock. Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit

Institutional Trading of Medpace

A number of large investors have recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Quarry LP acquired a new stake in Medpace in the third quarter valued at $35,000. Greenline Wealth Management LLC acquired a new stake in Medpace in the fourth quarter valued at $55,000. Group One Trading LLC lifted its stake in Medpace by 120.0% in the fourth quarter. Group One Trading LLC now owns 100 shares of the company’s stock valued at $56,000 after acquiring an additional 600 shares during the last quarter. Finally, Johnson Financial Group Inc. lifted its stake in Medpace by 115.7% in the third quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock valued at $57,000 after acquiring an additional 59 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.